Status:
COMPLETED
Study of the Effect of omega3 on Biomarkers of Cardiac Necrosis (CKMB and Troponin I) and Inflammation Marker (CRP) After Elective Percutaneous Coronary Intervention (PCI)
Lead Sponsor:
Shahid Beheshti University of Medical Sciences
Conditions:
Coronary Arteriosclerosis
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to investigate the effect of omega 3 on biomarkers of cardiac necrosis(CKMB and troponin I) and inflammation marker CRP.
Detailed Description
Percutaneous coronary intervention (PCI) has become the most common form of coronary revascularization worldwide. Although PCI is a safe procedure, it may have multiple risks including bleeding, coron...
Eligibility Criteria
Inclusion
- candidate of elective PCI
- treatment with aspirin at least 5 days before PCI
Exclusion
- high CKMB and troponin I level
- cardiac bypass in recent 3 months
- platelet count \< 70×10 9/L
- sever chronic renal failure
- active bleeding
- treatment with glycoprotein IIb/IIIa inhibitors during PCI
- treatment with bivalirudin during PCI
- sensitivity to aspirin and clopidogrel
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2012
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT01521845
Start Date
January 1 2012
End Date
May 1 2012
Last Update
December 10 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Moddaress Hospital
Tehran, Tehran Province, Iran